Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical …
…, J Yan, L Edwards, RL Parker, L Denny, M Giffear… - The Lancet, 2015 - thelancet.com
Background Despite preventive vaccines for oncogenic human papillomaviruses (HPVs),
cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can …
cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can …
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
…, X Shen, RL Parker, JC Lee, M Giffear… - Science translational …, 2012 - science.org
Despite the development of highly effective prophylactic vaccines against human papillomavirus
(HPV) serotypes 16 and 18, prevention of cervical dysplasia and cancer in women …
(HPV) serotypes 16 and 18, prevention of cervical dysplasia and cancer in women …
Tolerability of intramuscular and intradermal delivery by CELLECTRA® adaptive constant current electroporation device in healthy volunteers
…, SE Daniels, P Tebas, AS Khan, M Giffear… - Human vaccines & …, 2013 - Taylor & Francis
DNA vaccines are being developed as a potentially safe and effective immunization platform.
However, translation of DNA vaccines into a clinical setting has produced results that have …
However, translation of DNA vaccines into a clinical setting has produced results that have …
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in …
MP Mammen Jr, P Tebas, J Agnes, M Giffear… - MedRxiv, 2021 - medrxiv.org
Background Vaccines against SARS-CoV-2 are still urgently needed as only 5% of the global
population has been vaccinated. Here we report the safety and immunogenicity of a DNA …
population has been vaccinated. Here we report the safety and immunogenicity of a DNA …
SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial
…, J Agnes, P Tebas, M Giffear… - The Journal of …, 2022 - academic.oup.com
Background Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines that are safe and effective as primary vaccines and boosters remain urgently needed …
vaccines that are safe and effective as primary vaccines and boosters remain urgently needed …
[HTML][HTML] Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
…, K Broderick, K Marcozzi-Pierce, M Giffear… - Molecular Therapy …, 2016 - cell.com
We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA
immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a …
immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a …
Safety, bioavailability, and pharmacokinetics of VGX‐1027—A novel oral anti‐inflammatory drug in healthy human subjects
…, S Menacherry, MC Diehl, MD Giffear… - … in drug development, 2016 - Wiley Online Library
VGX‐1027, a novel oral immune modulator, is under development for the treatment of
rheumatoid arthritis. The safety, tolerability, and pharmacokinetics of single (1–800 mg) and …
rheumatoid arthritis. The safety, tolerability, and pharmacokinetics of single (1–800 mg) and …
DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results …
…, J Yan, K Kraynyak, A Sylvester, M Giffear… - … for ImmunoTherapy of …, 2014 - Springer
The Phase II study, designated HPV-003 (NCT01304524), assessed the safety and efficacy
of VGX-3100 in 167 women with biopsy-proven cervical intraepithelial neoplasia (CIN) 2 or …
of VGX-3100 in 167 women with biopsy-proven cervical intraepithelial neoplasia (CIN) 2 or …
Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial.
…, X Shen, C Knott, J Yan, K Broderick, A Khan, M Giffear… - 2014 - ascopubs.org
3101 Background: Despite the development of highly effective prophylactic vaccines against
human papillomavirus (HPV) types 16 and 18, prevention of cervical dysplasia and cancer …
human papillomavirus (HPV) types 16 and 18, prevention of cervical dysplasia and cancer …
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
P Tebas, J Agnes, M Giffear… - Open forum …, 2021 - academic.oup.com
Background DNA vaccines are safe, tolerable, elicit humoral and cellular responses, allow
for repeated dosing over time, are thermostable at room temperature, and are easy to …
for repeated dosing over time, are thermostable at room temperature, and are easy to …
